Chemically modified ASOs targeting lncRNA as novel therapeutics for the treatment of Melanoma


Claudia Sissi



Department of Pharmaceutical and Pharmacological Sciences, University of Padova




MELANOMA is the most lethal form of cutaneous cancer and the fifth most frequently diagnosed cancer. Emerging evidence support a functional role of various long-non coding RNAs (lncRNAs) in melanoma tumorigenesis according to different specific patterns.

With the aim to suppress cell proliferation, we will develop unprecedentedly modified antisense oligonucleotides (ASOs) as tunable tools to knockdown functionally active  lncRNA and potentiate immune responses.The selection of the target will be performed after a proper evaluation of the nuclear lncRNA landscape in melanoma cell lines and SHAPE analysis. In particular, short domains directly involved in supporting the 3D organization of the lncRNA will be considered as target for our novel ASOs.


Relevant Publications

  1. Ghezzo M, Sissi C.* (2023) Structural characterization of a cytosine-rich potential quadruplex forming sequence in the EGFR promoter. Journal of Thermal Analysis and Calorimetry, 148, 5375–5385

  2. Ghezzo M, Grigoletto L, Rigo R, Herdewijn P, Groaz E, Sissi C.* (2023)  Modulation of the tetrameric I-motif folding of C-rich Tetrahymena telomeric sequences by hexitol nucleic acid (HNA) modifications. Biochimie, Aug 7:S0300-9084(23)00194-3

  3. Ghezzo M, Trajkovski M, Plavec J, Sissi C.* (2023) A Screening Protocol for Exploring Loop Length Requirements for the Formation of a Three Cytosine-Cytosine+ Base-Paired i-Motif. Angew Chem Int Ed Engl., Aug 23:e202309327


Related Projects

PI: Walter Cabri